← back to search

Jan J. Cornelissen

European Medicines Agency · NL
Area of research
Hematology · Public Health, Environmental and Occupational Health
Research interest
Research interests include Hematopoietic Stem Cell Transplantation, Acute Myeloid Leukemia Research, Acute Lymphoblastic Leukemia research, and Chronic Myeloid Leukemia Treatments.
h-index
79
citations
31,838
works
610
NIH funding
primary concept
Medicine
email

Recent publications

Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling.
2024cited by 2position: contributordoi
Defining the role of real-world data in cancer clinical research: The position of the European Organisation for Research and Treatment of Cancer
European Journal of Cancer 2023cited by 86position: middledoi
Clinical Impact of Polymerase Chain Reaction–Based <i>Aspergillus</i> and Azole Resistance Detection in Invasive Aspergillosis: A Prospective Multicenter Study
Clinical Infectious Diseases 2023cited by 56position: middledoi
Upper and/or Lower Respiratory Tract Infection Caused by Human Metapneumovirus After Allogeneic Hematopoietic Stem Cell Transplantation
The Journal of Infectious Diseases 2023cited by 20position: middledoi
Impact of allele-level HLA matching on outcomes after double cord blood transplantation in adults with malignancies.
2023cited by 2position: contributordoi
Additional cytogenetic features determine outcome in patients allografted for <i>TP53</i> mutant acute myeloid leukemia
Cancer 2022cited by 52position: middledoi
Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity: an EBMT IEWP study
Blood 2022cited by 52position: middledoi
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Blood Advances 2021cited by 66position: middledoi
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of <scp>EBMT</scp> and the Spanish Myelofibrosis Registry
American Journal of Hematology 2021cited by 31position: middledoi
Stopping antibiotic therapy after 72 h in patients with febrile neutropenia following intensive chemotherapy for AML/MDS (safe study): A retrospective comparative cohort study
EClinicalMedicine 2021cited by 31position: middledoi
Optimizing Donor Choice and GVHD Prophylaxis in Allogeneic Hematopoietic Cell Transplantation.
2021cited by 19position: contributordoi
HEV infection in stem cell transplant recipients—retrospective study of EBMT Infectious Diseases Working Party
Bone Marrow Transplantation 2021cited by 11position: middledoi
Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation
The Lancet Haematology 2020cited by 535position: middledoi
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
Bone Marrow Transplantation 2020cited by 200position: middledoi
Inferior outcome of allogeneic stem cell transplantation for secondary acute myeloid leukemia in first complete remission as compared to de novo acute myeloid leukemia
Blood Cancer Journal 2020cited by 63position: middledoi
Post-transplantation cyclophosphamide GvHD prophylaxis after hematopoietic stem cell transplantation from 9/10 or 10/10 HLA-matched unrelated donors for acute leukemia
Leukemia 2020cited by 35position: middledoi
Prevalence of voriconazole-resistant invasive aspergillosis and its impact on mortality in haematology patients
Journal of Antimicrobial Chemotherapy 2019cited by 82position: middledoi
Exploratory Study of Predicted Indirectly ReCognizable HLA Epitopes in Mismatched Hematopoietic Cell Transplantations
Frontiers in Immunology 2019cited by 29position: middledoi
Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT)
Bone Marrow Transplantation 2018cited by 155position: middledoi
Ibrutinib for bridging to allogeneic hematopoietic cell transplantation in patients with chronic lymphocytic leukemia or mantle cell lymphoma: a study by the EBMT Chronic Malignancies and Lymphoma Working Parties
Bone Marrow Transplantation 2018cited by 71position: middledoi
Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of <scp>EBMT</scp>
British Journal of Haematology 2018cited by 35position: middledoi
Outcome after relapse of myelodysplastic syndrome and secondary acute myeloid leukemia following allogeneic stem cell transplantation: a retrospective registry analysis on 698 patients by the Chronic Malignancies Working Party of the European Society of Blood and Marrow Transplantation
Haematologica 2017cited by 127position: middledoi
Lipid-mediated Wnt protein stabilization enables serum-free culture of human organ stem cells
Nature Communications 2017cited by 76position: middledoi
Allogeneic stem cell transplantation in adult patients with acute myeloid leukaemia and 17p abnormalities in first complete remission: a study from the Acute Leukemia Working Party (ALWP) of the European Society for Blood and Marrow Transplantation (EBMT)
Journal of Hematology & Oncology 2017cited by 59position: middledoi
Allogeneic stem cell transplantation in acute lymphoblastic leukemia patients older than 60 years: a survey from the acute leukemia working party of EBMT
Oncotarget 2017cited by 30position: middledoi
Acute myeloid leukaemia
Nature Reviews Disease Primers 2016cited by 578position: middledoi
PCR-based detection of <i>Aspergillus fumigatus Cyp51A</i> mutations on bronchoalveolar lavage: a multicentre validation of the AsperGenius assay <sup>®</sup> in 201 patients with haematological disease suspected for invasive aspergillosis
Journal of Antimicrobial Chemotherapy 2016cited by 128position: middledoi
Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party
Leukemia 2016cited by 68position: middledoi
Achievement of complete remission predicts outcome of allogeneic haematopoietic stem cell transplantation in patients with chronic myelomonocytic leukaemia. A study of the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation
British Journal of Haematology 2015cited by 109position: middledoi
Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis
The Lancet Haematology 2015cited by 100position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Mohamad Mohty · Inserm12 papers (2012–2022)Arnon Nagler · University of Naples Federico II9 papers (2012–2022)Johan Maertens · Ospedale Policlinico San Martino8 papers (2013–2021)Nicolaus Kröger · Universität Ulm8 papers (2014–2022)Myriam Labopin · Inserm8 papers (2012–2022)Jakob Passweg · Centre Hospitalier Universitaire de Nantes7 papers (2013–2021)Didier Blaise · Institut Pprime7 papers (2015–2020)Jürgen Finke · University of Education Freiburg7 papers (2013–2017)Liisa Volin · University Hospital Heidelberg6 papers (2014–2017)Nicolaas Schaap · National Institute of Allergy and Infectious Diseases6 papers (2014–2022)Arnold Ganser · Radboud University Medical Center6 papers (2012–2020)Bronno van der Holt · Hovon5 papers (2012–2024)Sebastian Giebel · Medical University of Warsaw5 papers (2015–2022)Ibrahim Yakoub‐Agha · Inserm5 papers (2014–2020)Charles Craddock · University Hospitals Birmingham NHS Foundation Trust4 papers (2012–2022)Annalisa Ruggeri · European Organisation for Rare Diseases4 papers (2013–2020) · 4 papers (2014–2017)Vanderson Rocha · Fundação Pró-Sangue Hemocentro de São Paulo4 papers (2012–2023)Gèrard Socié · Institut de Psychiatrie et Neurosciences de Paris4 papers (2014–2020) · 4 papers (2012–2019)